Characterization of a monoclonal antibody (RJ5) against the immunodominant 41-kD antigen of Candida albicans. 1991

H D Shen, and K B Choo, and K W Yu, and W L Ling, and F C Chang, and S H Han
Department of Medical Research, Veterans General Hospital, Taipei, Taiwan.

A 41-kD component of Candida albicans was identified to be the major antigen radioimmunoprecipitated by antibodies with increased titers in the sera of patients with invasive candidiasis. A mouse monoclonal antibody (RJ5) was generated which, by immunoblotting, showed positive reactivity to the immunoprecipitated 41-kD component. By two-dimensional gel electrophoresis and immunoblotting, MoAb RJ5 was shown to react with different isoforms of the 41-kD component with pI values from 6.1 to 6.9. Furthermore, MoAb RJ5 showed positive reactivity to cytoplasmic antigens of C. albicans by frozen section and immunoperoxidase staining. By SDS-polyacrylamide gel electrophoresis and immunoblotting, MoAb RJ5 showed no cross-reactivity to antigens of Candida tropicalis and Candida parapsilosis. The epitope of the 41-kD molecule recognized by MoAb RJ5 was susceptible to treatment of proteinase K at concentrations of greater than or equal to 5 micrograms/ml, and was relatively resistant to periodate oxidation with concentration of NaIO4 up to 20 mM. This MoAb may be useful in the purification and characterization of the immunodominant 41-kD antigen of C. albicans, and as a probe in the detection of Candida antigens in the sera of patients with invasive candidiasis.

UI MeSH Term Description Entries
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D011233 Precipitin Tests Serologic tests in which a positive reaction manifested by visible CHEMICAL PRECIPITATION occurs when a soluble ANTIGEN reacts with its precipitins, i.e., ANTIBODIES that can form a precipitate. Precipitin Test,Test, Precipitin,Tests, Precipitin
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D002177 Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed) Candida Infection,Moniliasis,Candida Infections,Candidiases,Infection, Candida,Moniliases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D000946 Antigens, Fungal Substances of fungal origin that have antigenic activity. Fungal Antigen,Fungal Antigens,Antigen, Fungal
D015151 Immunoblotting Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies. Dot Immunoblotting,Electroimmunoblotting,Immunoelectroblotting,Reverse Immunoblotting,Immunoblotting, Dot,Immunoblotting, Reverse,Dot Immunoblottings,Electroimmunoblottings,Immunoblottings,Immunoblottings, Dot,Immunoblottings, Reverse,Immunoelectroblottings,Reverse Immunoblottings

Related Publications

H D Shen, and K B Choo, and K W Yu, and W L Ling, and F C Chang, and S H Han
June 2005, Hybridoma (2005),
H D Shen, and K B Choo, and K W Yu, and W L Ling, and F C Chang, and S H Han
May 1985, Lancet (London, England),
H D Shen, and K B Choo, and K W Yu, and W L Ling, and F C Chang, and S H Han
May 1999, Clinical and diagnostic laboratory immunology,
H D Shen, and K B Choo, and K W Yu, and W L Ling, and F C Chang, and S H Han
January 2015, World journal of microbiology & biotechnology,
H D Shen, and K B Choo, and K W Yu, and W L Ling, and F C Chang, and S H Han
April 1988, The Journal of experimental medicine,
H D Shen, and K B Choo, and K W Yu, and W L Ling, and F C Chang, and S H Han
June 1990, Immunology and cell biology,
H D Shen, and K B Choo, and K W Yu, and W L Ling, and F C Chang, and S H Han
September 2003, Infection and immunity,
H D Shen, and K B Choo, and K W Yu, and W L Ling, and F C Chang, and S H Han
December 1988, Journal of medical microbiology,
H D Shen, and K B Choo, and K W Yu, and W L Ling, and F C Chang, and S H Han
June 2005, Current molecular medicine,
Copied contents to your clipboard!